Author Credentials

Ahmed Amro MD Kanaan Mansoor MD Mohammad Amro MD Amal Sobeih MD Obadah Aqtash MD Hisham Hirzallah MD Alaa Gabi MD Madhulika Urella MD Waseem Ahmed MD Sandra Shenouda MD Rameez Sayyed MD


Prasugrel, inappropriate use, Coronary intervention, DAPT


Cardiology | Critical Care | Medicine and Health Sciences


Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI. This retrospective study aims to assess the frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs more attention as inappropriate use may result in significant morbidity.